Salarius Pharmaceuticals Inc Aktie News

Patient Enrollment Resumed in the Investigator-initiated Phase 1/2 Clinical Trial of Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers

Additional Ewing Sarcoma Patient in Company's Phase 1/2 Sarcoma Trial Achieves Partial Response; Objective Response Rate Among First-Relapse Ewing Patients Treated with Seclidemstat, Topotecan and Cyclophosphamide Reaches 60% Additional Ewing Sarcoma Patient in Company's Phase 1/2 Sarcoma Trial Achieves Partial Response; Objective Response Rate Among First-Relapse Ewing Patients Treated with Se...

FDA briefing included new Ewing sarcoma clinical data from ongoing investigation where 60% of first-relapse patients achieved disease control and have not progressed after at least 14.5, 19.7 and 22.8 months

The trial will assess the safety and preliminary efficacy of Salarius' novel targeted protein degrader SP-3164; Patient dosing expected to begin in 2H 2023

SP-3164 demonstrates compelling antitumor activity in animal models of follicular lymphoma and compelling antitumor activity in animal models of multiple myeloma

Data to be presented at AACR demonstrate significant SP-3164 anticancer activity in both non-Hodgkin Lymphoma and Multiple Myeloma cell lines and animal models

Preclinical data show synergistic activity for the targeted protein degrader SP-3164 with rituximab in non-Hodgkin's lymphomas, and significantly better performance than standard-of-care treatment

Dr. Aundrietta Duncan to discuss mechanism of action and SP-3164 activity in cancer models